2022
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher V, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances 2022, 6: 828-847. PMID: 34551064, PMCID: PMC8945306, DOI: 10.1182/bloodadvances.2021004881.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaPost-HCT outcomesRisk classificationAdverse-risk acute myeloid leukaemiaAdverse-risk diseaseFirst complete remissionIntermediate-risk diseaseLeukemia-free survivalAdjusted multivariable analysisCell transplantation outcomesRisk of relapseNovel treatment strategiesCIBMTR databaseComplete remissionOverall survivalMultivariable analysisRisk stratificationTransplantation outcomesMyeloid leukemiaTreatment strategiesPatientsFinal analysisAdverse riskKMT2ADisease
2019
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant
Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research In Translational Medicine 2019, 67: 51-55. PMID: 30683577, PMCID: PMC7735254, DOI: 10.1016/j.retram.2019.01.001.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAgedCytomegalovirusCytomegalovirus InfectionsFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHLA-DP AntigensHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesRetrospective StudiesRisk FactorsTransplant RecipientsTransplantation ImmunologyTransplantation, HomologousVirus ActivationYoung AdultConceptsHLA-DPB1 mismatchingCMV reactivationOverall survivalRisk of aGVHDRisk of relapseCMV serostatusHLA-DPIncrease riskAllogeneic hematopoietic stem cell transplantationAllogeneic stem cell transplantHematopoietic stem cell transplantationMD Anderson Cancer CenterGVHD target tissuesHLA-DP mismatchesRecipient CMV serostatusRisk of GVHDStem cell transplantStem cell transplantationHLA-DP moleculesAnderson Cancer CenterGVHD incidenceCumulative incidenceCell transplantMultivariable analysisCancer Center